Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 07/11/2024 at 18:45, 1 year 10 months ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF

published on 07/03/2024 at 07:35, 1 year 10 months ago

Theranexus, CRNL et CERMEP lauréats du projet "Pacte de recherche 2024" d'Auvergne-Rhône-Alpes

Recherche Auvergne-Rhône-Alpes Theranexus Neurologie Neuroimagerie
BRIEF

published on 07/03/2024 at 07:35, 1 year 10 months ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 10 months ago

THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET " PACTE DE RECHERCHE 2024 " DE LA REGION AUVERGNE-RHÔNE-ALPES
Theranexus, CRNL, and CERMEP win 'Pacte de recherche 2024' project in Auvergne-Rhône-Alpes to develop new neuroimaging tools for rare neurological diseases treatment

Theranexus Rare Neurological Diseases Neuroimaging CRNL CERMEP
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 10 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 11 months ago

Theranexus et BBDF annoncent des résultats positifs à 18 mois pour Batten-1 dans une étude de phase 1/2

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 06/06/2024 at 07:35, 1 year 11 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 11 months ago

Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3)

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 11 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 2 years ago

Theranexus dévoile son document d'enregistrement universel pour 2023

2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares

Accesswire

Published on 05/23/2026 at 19:45, 1 hour 56 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 18 hours 26 minutes ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 18 hours 41 minutes ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 19 hours 16 minutes ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 19 hours 16 minutes ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 5 hours 11 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 5 hours 44 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 23 hours 36 minutes ago

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 23 hours 36 minutes ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 1 hour ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices

Les Echos

Published on 05/22/2026 at 19:35, 1 day 2 hours ago

PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 3 hours ago

Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 3 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 8 hours ago

Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 8 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026

View all LES ECHOS COMFI WIRE